Positive impactSector
ICICI Securities sees telecom among Nifty's biggest sectors as tariff hike nears
CNBC-TV18 1 hr ago·28 Oct 2026, 3:54 am
ICICI Securities has identified Piramal Pharma as a key investment theme, highlighting the company's expanding Contract Development and Manufacturing Organization (CDMO) business. This sector focus comes as the brokerage anticipates a significant 16-20% tariff hike in the telecom sector, which is expected to boost cash flows and improve 5G monetization. For Piramal Pharma, the emphasis is on its growing CDMO capabilities, which allow it to serve global pharmaceutical companies.
This move by ICICI Securities underscores the brokerage's confidence in the company's ability to capitalize on the global demand for pharmaceutical manufacturing services. The telecom sector's potential growth, driven by tariff hikes, is seen as a broader market trend that could indirectly benefit the pharmaceutical industry by boosting overall economic activity. Investors should watch for updates on Piramal Pharma's CDMO contracts and the telecom sector's tariff implementation.
Affected stocks
Bullish2 stocks
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Piramal Pharma (PPLPHARMA).
- Category: Sector.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
- Also mentions RADICO.
Why it matters
A meaningful update for Piramal Pharma worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
